Induction Therapy for Newly Diagnosed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Multiple Myeloma Hub on Twitter: "PFS from 1st randomization: 53% reduction in risk of progression or death with D-VTd. OS: data immature. Non-hematological toxicity same between arms. Philippe Moreau concludes D- VTd should
EMN18 - European Myeloma Network
Newly Diagnosed: D + VMP Treatment | DARZALEX® IV (daratumumab)
Cureus | Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis | Article
Multiple Myeloma Hub on Twitter: "#ASCO21 | Patients treated with dara+VTd/ dara achieved higher responses and MRD negativity rates. 📢Share your experience with dara+VTd! How might the CASSIOPEIA results impact other trials exploring
Vantaggi dall'aggiunta di daratumumab a VTd nei pazienti con MM eleggibili al trapianto - Ematoinfo
ottobre 2019 - Daratumumab in aggiunta a bortezomib, talidomide e desametasone (VTd) prima e dopo trapianto autologo di cellule staminali migliora i tassi di risposta e la PFS rispetto a VTd: risultati
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
NEW TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED RELAPSE / REFRACTORY MULTIPLE MYELOMA
Presentazione di PowerPoint
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
NEW TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED RELAPSE / REFRACTORY MULTIPLE MYELOMA
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
Twitter \ Multiple Myeloma Hub على تويتر: "CONGRESS | #COMy20 | MM Hub SC member Philippe Moreau, @UnivNantes, discussed novel induction regimens to optimize outcomes to transplant. The benefit of KRd, Dara-VTd
Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
A20-15 - Daratumumab - Extract of dossier assessment - Version 1.0
NEW TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED RELAPSE / REFRACTORY MULTIPLE MYELOMA
Caso Clínico: Mieloma Múltiplo elegível a TMO
Daratumumab maintenance after treatment with VTd w/DARA and ASCT in pts with NDMM: CASSIOPEIA Part 2 - YouTube
MGUS E MIELOMA MULTIPLO: UPDATE DIAGNOSTICO- TERAPEUTICO
How I treat relapsed multiple myeloma - ScienceDirect
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
